Likang Life Sciences presents AI-driven cancer therapies at Abu Dhabi summit
Biotechnology firm Likang Life Sciences showcased its personalized immunotherapy platform at the Abu Dhabi Future Health Summit held in October.
Beijing-based Likang Life Sciences participated in the Abu Dhabi Future Health Summit, held from October 20 to 22 at the ADNEC Centre, to demonstrate its progress in AI-enabled cancer immunotherapies.
The company is developing specialized treatments that utilize artificial intelligence to create personalized immune responses against tumors. The event provided a platform for Likang to connect with regional healthcare stakeholders as it pursues broader international growth.
By highlighting its technical capabilities in Abu Dhabi, Likang aims to secure its position in the competitive field of biotechnology and precision medicine as it continues to advance its clinical development pipeline.